RT Journal Article
SR Electronic
T1 Anakinra To Prevent Respiratory Failure In COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.28.20217455
DO 10.1101/2020.10.28.20217455
A1 Evdoxia Kyriazopoulou
A1 Periklis Panagopoulos
A1 Simeon Metallidis
A1 George N. Dalekos
A1 Garyfallia Poulakou
A1 Nikolaos Gatselis
A1 Eleni Karakike
A1 Maria Saridaki
A1 Georgia Loli
A1 Aggelos Stefos
A1 Danai Prasianaki
A1 Sarah Georgiadou
A1 Olga Tsachouridou
A1 Vasileios Petrakis
A1 Konstantinos Tsiakos
A1 Maria Kosmidou
A1 Vassiliki Lygoura
A1 Maria Dareioti
A1 Haralampos Milionis
A1 Ilias C. Papanikolaou
A1 Karolina Akinosoglou
A1 Dimitra-Melia Myrodia
A1 Areti Gravvani
A1 Aliki Stamou
A1 Theologia Gkavogianni
A1 Konstantina Katrini
A1 Theodoros Marantos
A1 Ioannis P. Trontzas
A1 Konstantinos Syrigos
A1 Loukas Chatzis
A1 Stamatios Chatzis
A1 Nikolaos Vechlidis
A1 Christina Avgoustou
A1 Stamatios Chalvatzis
A1 Miltiades Kyprianou
A1 Jos W. M. van der Meer
A1 Jesper Eugen-Olsen
A1 Mihai G. Netea
A1 Evangelos J. Giamarellos-Bourboulis
YR 2020
UL http://medrxiv.org/content/early/2020/10/29/2020.10.28.20217455.abstract
AB Introduction The management of pneumonia caused by SARS-CoV-2 should rely on early recognition of the risk for progression to severe respiratory failure (SRF) and its prevention. We investigated if early suPAR (soluble urokinase plasminogen activator receptor)-guided anakinra treatment could prevent COVID-19-assocated SRF.Methods In this open-label prospective trial, 130 patients admitted with SARS-CoV-2 pneumonia SARS-CoV-2 and suPAR levels ≥6 μg/l were assigned to subcutaneous anakinra 100mg once daily for 10 days. The primary outcome was the incidence of SRF at day 14. Secondary outcomes were 30-day mortality, changes in sequential organ failure assessment (SOFA) score, of cytokine-stimulation pattern and of circulating inflammatory mediators. Equal number of propensity score-matched comparators for comorbidities, severity on admission and standard-of care (SOC) were studied.Results The incidence of SRF was 22.3% (95% CI, 16.0-30.2%) among anakinra-treated patients and 59.2% (95% CI, 50.6-67.3%; P: 4.6 x 10−8) among SOC comparators (hazard ratio, 0.30; 95%CI, 0.20-0.46). 30-day mortality was 11.5% (95% CI, 7.1-18.2%) and 22.3% (95% CI, 16.0-30.2%) respectively (hazard ratio 0.49; 95% CI 0.25-0.97%; P: 0.041). Anakinra treatment was associated with decrease in SOFA score and in circulating interleukin (IL)-6, sCD163 and sIL2-R; the serum IL-10/IL-6 ratio on day 7 was inversely associated with the change in SOFA score. Duration of stay at the intensive care unit and at hospital was shortened compared to the SOC group; the cost of hospitalization was decreased.Conclusions Early suPAR-guided anakinra treatment is associated with decrease of the risk for SRF and restoration of the pro- /anti-inflammatory balance.Trial Registration ClinicalTrials.gov, NCT04357366Competing Interest StatementPeriklis Panagopoulos has received honoraria from GILEAD Sciences, Janssen, and MSD. George N. Dalekos has acted as Advisor/Lecturer for Abbvie, Bristol-Myers Squibb, Gilead, Novartis, Roche, Amgen, MSD, Janssen, Ipsen and Pfizer, has received Grant support from Bristol-Myers Squib, Gilead, Roche, Janssen, Abbvie and Bayer and was or is currently PI in National and International Protocols sponsored by Abbvie, Bristol-Myers Squibb, Novartis, Gilead, Novo Nordisk, Genkyotex, Regulus Therapeutics Inc, Tiziana Life Sciences, Bayer, Astellas, Ipsen, Pfizer and Roche. G. Poulakou has received independent educational grants from Pfizer, MSD, Angelini, and Biorad. Haralampos Milionis reports receiving honoraria, consulting fees and non-financial support from healthcare companies, including Amgen, Angelini, Bayer, Mylan, MSD, Pfizer, and Servier. Jesper Eugen-Olsen is a cofounder, shareholder and CSO of ViroGates A7S, Denmark and is named inventor on patents on suPAR owned by Copenhagen University Hospital Hvidovre, Denmark. Mihai G. Netea is supported by an ERC Advanced Grant (#833247) and a Spinoza grant of the Netherlands Organization for Scientific Research. He has also received independent educational grants from TTxD, GSK and ViiV HealthCare. E.J. Giamarellos-Bourboulis has received honoraria from Abbott CH, Angelini Italy, InflaRx GmbH, MSD Greece, XBiotech Inc., and BRAHMS GmbH (Thermo Fisher Scientific); independent educational grants from AbbVie Inc, Abbott CH, Astellas Pharma Europe, AxisShield, bioMerieux Inc, Novartis, InflaRx GmbH, and XBiotech Inc; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). The other authors do not report any conflict of interest.Clinical TrialNCT04357366Funding StatementThe trial was conducted by the Hellenic Institute for the Study of Sepsis (HISS) and funded in part by HISS, by Technomar Shipping Inc, by Swedish Orphan Biovitrum AB and by the Horizon 2020 RISKinCOVID grant. The funders had no role in the design, conduct, analysis and interpretation of data, and decision to publish.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SAVE is an ongoing open-label non-randomized trial conducted in six study sites in Greece (EudraCT number 2020-001466-11; National Ethics Committee approval 38/20; National Organization for Medicines approval ISO 28/20; ClinicalTrials.gov registration NCT04357366). Comparators receiving SOC treatment were hospitalized at the same time period in eight other study sites who were participating in the registry of the Hellenic Sepsis Study Group without participating in the SAVE trial (www.sepsis.gr). The trial was conducted by the Hellenic Institute for the Study of Sepsis (HISS) and funded in part by HISS, by Technomar Shipping Inc, by Swedish Orphan Biovitrum AB and by the Horizon 2020 RISKinCOVID grant. The funders had no role in the design, conduct, analysis and interpretation of data, and decision to publish. The laboratory of Immunology of Infectious Diseases of the 4th Department of Internal Medicine at ATTIKON University General Hospital served as a central laboratory for the study. The initial draft of the manuscript was written by the first and the last author. All authors vouch for the adherence of the trial to the protocol and first and last author vouch for the accuracy and completeness of the data and analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available from the senior author (E. J Giamarellos-Bourboulis) upon request (egiamarel{at}med.uoa.gr)